Relay Therapeutics, Inc.
Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage biopharmaceutical company developing small-molecule precision medicines for cancer and genetic diseases. Its Dynamo platform combines computational and experimental methods to study protein motion and identify drug candidates for genetically validated targets. The… From the company’s description.
Over the twelve months to Sep 30, 2026, Relay Therapeutics, Inc. reported revenue of $10.35M, up 23.9% from a year earlier, and a net loss of $293.63M. Operations used $214.02M in cash. In fiscal 2025, it reported revenue of $15.36M, up 53.4% from fiscal 2024, and a net loss of $276.48M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Relay Therapeutics, Inc. does
In the company’s own words
Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage biopharmaceutical company developing small-molecule precision medicines for cancer and genetic diseases. Its Dynamo platform combines computational and experimental methods to study protein motion and identify drug candidates for genetically validated targets. The lead candidate, zovegalisib, is in clinical development for PI3Kα-mutated breast cancer and vascular anomalies; other programs include an NRAS-selective inhibitor for solid tumors and a non-inhibitory chaperone for Fabry disease. Relay has licensed global development and commercialization rights for its FGFR2 inhibitor lirafugratinib to Elevar Therapeutics, while retaining rights to its other active precision-medicine programs. The company’s research and development pipeline spans precision oncology and genetic diseases, and it has no products approved for commercial sale. Its Dynamo platform and pipeline reflect the company’s focus on targets linked to disease-causing genetic alterations.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- CAMBRIDGE, MA
- Fiscal year end
- December
- CIK
- 1812364
- SIC
- 2836
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Relay Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Relay Therapeutics, Inc. · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Relay Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Relay Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Relay Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Relay Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”